You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
394 Interleukin-8–neutralizing monoclonal antibody BMS-986253 plus nivolumab (NIVO) in biomarker-enriched, primarily anti–PD-(L)1–experienced patients with advanced cancer: initial phase 1 results

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020326053
Dec 202034011
Jan 202141018
Feb 202128011
Mar 202194022
Apr 202146018
May 202119043
Jun 20210017
Jul 20211017
Aug 20210011
Sep 20210023
Oct 202176033
Nov 202192027
Dec 20214808
Jan 202292017
Feb 202271024
Mar 2022134030
Apr 2022160027
May 2022130020
Jun 2022127026
Jul 2022126023
Aug 2022143022
Sep 202282015
Oct 2022125013
Nov 2022122022
Dec 2022138016
Jan 2023138023
Feb 2023110015
Mar 2023128014
Apr 2023132016
May 2023189028
Jun 202390013
Jul 2023100018
Aug 2023108015
Sep 2023150011
Oct 2023150018
Nov 2023146016
Dec 2023134012
Jan 20244402
Feb 202417601
Mar 2024160014
Apr 202452014
May 20249609
Jun 20248002
Jul 2024110013
Aug 202410008
Sep 2024144018
Oct 2024120014
Nov 2024122016
Dec 2024180017
Jan 2025168021
Feb 202558018
Mar 20250021
Apr 2025006
May 2025007
Jun 2025005
Total54400972